Oxford Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Oxford Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.21M	Buy	+70,212	New	+$2.07M	1.09%	6
2025 Q3	–	Sell	-20,201	Closed	-$438K	–	502
2025 Q2	$438K	Buy	+20,201	New	+$477K	0.14%	235
2020 Q1	–	Sell	-259,439	Closed	-$973K	–	451
2019 Q4	$973K	Buy	259,439 +108,409	+72%	+$507K	0.03%	874
2019 Q3	$802K	Sell	151,030 -24,923	-14%	-$133K	0.02%	1051
2019 Q2	$676K	Buy	+175,953	New	+$760K	0.01%	1149
2018 Q4	–	Sell	-353,962	Closed	-$1.34M	–	1828
2018 Q3	$1.34M	Sell	353,962 -336,438	-49%	-$1.05M	0.03%	875
2018 Q2	$2.15M	Buy	690,400 +38,801	+6%	+$118K	0.04%	623
2018 Q1	$1.56M	Buy	651,599 +476,132	+271%	+$1.58M	0.03%	713
2017 Q4	$696K	Buy	175,467 +37,138	+27%	+$123K	0.02%	1079
2017 Q3	$344K	Buy	138,329 +52,161	+61%	+$143K	0.01%	1309
2017 Q2	$238K	Buy	86,168 +27,228	+46%	+$56.8K	﹤0.01%	1317
2017 Q1	$115K	Buy	58,940 +34,181	+138%	+$43.5K	﹤0.01%	1351
2016 Q4	$26K	Buy	+24,759	New	+$28.3K	﹤0.01%	753
2016 Q3	–	Sell	-180,721	Closed	-$128K	–	779
2016 Q2	$128K	Buy	180,721 +6,140	+4%	+$4.95K	﹤0.01%	723
2016 Q1	$204K	Buy	+174,581	New	+$271K	0.01%	710

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Oxford Asset Management's CPRX Position: Q2 2026 in Review

Oxford Asset Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 70,212 shares worth $2.21M. The stake represents 1.09% of the portfolio and ranks #6 among its holdings. This is a return to the name: Oxford Asset Management previously reported a position in CPRX as recently as Q2 2025.

Oxford Asset Management first reported a position in CPRX in Q1 2016 and has held it in 15 quarters since. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Oxford Asset Management held 70,212 shares of Catalyst Pharmaceutical worth $2.21M as of Q2 2026.
Catalyst Pharmaceutical was a new Oxford Asset Management position in Q2 2026.
Catalyst Pharmaceutical made up 1.09% of Oxford Asset Management's portfolio in Q2 2026, its #6 holding.
Oxford Asset Management first reported a position in Catalyst Pharmaceutical in Q1 2016 and has held it in 15 quarters since.
395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.